Skip to main content
SpringerLink
Log in

Evidence of Clinical Activity for Cetuximab Combined with Irinotecan in a Patient with Refractory Anal Canal Squamous-Cell Carcinoma: Report of a Case

  • Published:
Diseases of the Colon & Rectum

Abstract

Because of the high cure rate of localized anal cancers from combined modality treatment, there is little that is known for the treatment of patients who progress to have metastatic disease. Treatments currently used are based on activity demonstrated in other cancers with similar histology. Cetuximab, a molecular-targeted therapy, is an antibody directed against epidermal growth factor receptor that has demonstrated anticancer activity in several cancers. We report a female patient with refractory anal cancer who achieved an excellent response to the combination of cetuximab and irinotecan after having failed single-agent irinotecan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. A Jemal T Murray E Ward et al. (2005) ArticleTitleCancer statistics, 2005 CA Cancer J Clin 55 10–30 Occurrence Handle15661684 Occurrence Handle10.3322/canjclin.55.1.10

    Article  PubMed  Google Scholar 

  2. DP Ryan CC Compton RJ Mayer (2000) ArticleTitleCarcinoma of the anal canal N Engl J Med 342 792–800 Occurrence Handle10717015 Occurrence Handle10.1056/NEJM200003163421107 Occurrence Handle1:STN:280:DC%2BD3c7ms1GqtQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  3. BJ Cummings (1996) ArticleTitleAnal canal cancer: current treatment and results Ann Acad Med Singapore 25 460–467 Occurrence Handle8876916 Occurrence Handle1:STN:280:DyaK2s%2FjtV2rug%3D%3D

    PubMed  CAS  Google Scholar 

  4. ND Nigro HG Seydel B Considine et al. (1983) ArticleTitleCombined preoperative radiation and chemotherapy for squamous-cell carcinoma of the anal canal Cancer 51 1826–1829 Occurrence Handle6831348 Occurrence Handle10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L Occurrence Handle1:STN:280:DyaL3s7lsFSmsA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  5. RS Herbst A Onn J Mendelsohn (2003) ArticleTitleThe role of growth factor signaling in malignancy Cancer Treat Res 115 19–72 Occurrence Handle12613192 Occurrence Handle1:CAS:528:DC%2BD3sXnt12gs70%3D Occurrence Handle10.1007/0-306-48158-8_2

    Article  PubMed  CAS  Google Scholar 

  6. F Kabbinavar HI Hurwitz L Fehrenbacher et al. (2003) ArticleTitlePhase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60–65 Occurrence Handle12506171 Occurrence Handle10.1200/JCO.2003.10.066 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWru7Y%3D

    Article  PubMed  CAS  Google Scholar 

  7. ES Kim EE Vokes MS Kies (2004) ArticleTitleCetuximab in cancers of the lung and head & neck Semin Oncol 31 61–67 Occurrence Handle14981582 Occurrence Handle10.1053/j.seminoncol.2003.12.016 Occurrence Handle1:CAS:528:DC%2BD2cXisFelsbg%3D

    Article  PubMed  CAS  Google Scholar 

  8. D Cunningham Y Humblet S Siena et al. (2004) ArticleTitleCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337–345 Occurrence Handle15269313 Occurrence Handle10.1056/NEJMoa033025 Occurrence Handle1:CAS:528:DC%2BD2cXlvFGitbk%3D

    Article  PubMed  CAS  Google Scholar 

  9. CC Bancroft Z Chen J Yeh et al. (2002) ArticleTitleEffects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck Squamous-cell carcinoma lines Int J Cancer 99 538–548 Occurrence Handle11992543 Occurrence Handle10.1002/ijc.10398 Occurrence Handle1:CAS:528:DC%2BD38XjsFansLw%3D

    Article  PubMed  CAS  Google Scholar 

  10. D Busse FM Yakes AE Lenferink et al. (2001) ArticleTitleTyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance Semin Oncol 28 47–55 Occurrence Handle11706396 Occurrence Handle10.1016/S0093-7754(01)90282-9 Occurrence Handle1:CAS:528:DC%2BD3MXpt1Wgu7g%3D

    Article  PubMed  CAS  Google Scholar 

  11. CL Arteaga (2001) ArticleTitleThe epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J Clin Oncol 19 32S–40S Occurrence Handle11560969 Occurrence Handle1:CAS:528:DC%2BD3MXnsVKqtr0%3D

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, Texas, 77030-4009, USA

    Lan K. Phan M.P.A.S., P.A.-C. & Paulo M. Hoff M.D., F.A.C.P.

Authors
  1. Lan K. Phan M.P.A.S., P.A.-C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paulo M. Hoff M.D., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Reprints are not available.

About this article

Cite this article

Phan, L.K., Hoff, P.M. Evidence of Clinical Activity for Cetuximab Combined with Irinotecan in a Patient with Refractory Anal Canal Squamous-Cell Carcinoma: Report of a Case. Dis Colon Rectum 50, 395–398 (2007). https://doi.org/10.1007/s10350-006-0786-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10350-006-0786-9

Key words

Search

Navigation